We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Why are osteoporosis patients treated with antiresorptive therapies considered like oncology patients regarding their oral health care?
- Authors
Cordova, Luis A.; González-Quintanilla, David; Heymann, Dominique
- Abstract
The article explains why osteoporosis patients treated with antiresorptive (AR) drugs are considered like oncology patients regarding their oral health care. It discusses the efficacy of biphosphonates and denosumab in treating osteoporosis. It refers to AR-related osteonecrosis of the jaw (ARONJ) as a complication in AR-treated patients and cites the lack knowledge about differential risks associated with the development of ARONJ between osteoporosis and cancer exposed to oral treatments.
- Subjects
OSTEOPOROSIS prevention; BONE fracture prevention; JAW diseases; RISK assessment; DENTAL care; BONE resorption; DIPHOSPHONATES; BONE density; CANCER patients; MONOCLONAL antibodies; OSTEOCLASTS; OSTEOPOROSIS; OSTEONECROSIS; ORAL health; DISEASE risk factors
- Publication
Osteoporosis International, 2024, Vol 35, Issue 9, p1677
- ISSN
0937-941X
- Publication type
Article
- DOI
10.1007/s00198-024-07173-7